Recon: RFK Jr. launches review of mifepristone; FDA approves Lilly’s advanced breast cancer drug

• US FDA approves Eli Lilly's therapy for advanced breast cancer (Reuters)
• From an elixir for ‘little hotheads’ to deadly overdoses, how Tylenol became a medicinal scapegoat (STAT)
• Bristol Myers to sell psoriasis drug at over 80% discount to some US patients (Reuters)
• RFK Jr. Mulls Adding Autism Symptoms to Vaccine Injury Program (Bloomberg)
• Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stance (Reuters)
• Obama rebukes Trump’s Tylenol claims: ‘Violence against the truth’ (The Hill)
• Thune ‘very concerned’ about Trump, RFK Jr. Tylenol, autism claims (The Hill)
• RFK Jr. Opens Investigation Into the Safety of the Abortion Pill (Bloomberg)
• MCED Act Advances In US House Committees, Exact Sciences Cancerguard Poised To Benefit (MedTech Insight)

• UK govt reveals £50M R&D fund as it attempts to assuage drugmakers’ concerns (Endpoints)
• Merck KGaA CEO Belén Garijo to leave next May, when electronics unit leader will take the helm (Endpoints)
• Blackstone, Warburg Said to Vie for CVC-Backed Sebia Stake (Bloomberg)
• Medtronic expands AI, robotics hub in London; Virtuoso robot gets FDA breakthrough status (MedTech Dive)
• MedTech Industry Makes Case For Smarter Governance To Avoid EU Regulatory Bottlenecks (MedTech Insight)

• Moderna crowns new UK facility as other drugmakers pile on the kingdom (Fierce Pharma)
• Uniqure and its Huntington’s therapy win the week in biotech (STAT)
• Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study (STAT)
• Eli Lilly halts trial testing experimental muscle-preserving drug with Zepbound (Reuters)
• Pfizer's Metsera deal could spark more M&A for pharmas 'tiptoeing into obesity' (Endpoints)
• Can a virtual team of researchers break a 40-year logjam in this rare cancer? (Endpoints)
• Catalent moves into new HQ; Fujifilm opens factory in North Carolina (Endpoints)
• Thyme Care hits $1B valuation in latest funding round (Endpoints)
• PepGen seeks funds on the back of early-stage data in muscle wasting disease (Endpoints)
• Hansa’s kidney transplant drug succeeds in Phase 3 trial in US (Endpoints)
• Why Lower Doses of Cancer Drugs Remain Elusive (Bloomberg)
• Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work (Bloomberg)

• Inside NYU’s AI-powered plan to catch osteoporosis with repurposed CT scans (STAT)
• US medtech stocks fall as Trump administration opens import probe (Reuters)
• Epic embraces the newfound attention of its AI tools (Endpoints)
• US Eyes Robotics, Medical Gear in Latest Tariff Probes (Bloomberg)
• Que Dallara on Medtronic’s diabetes spinoff, pipeline and Abbott partnership (MedTech Dive)
• Stryker CEO Lobo: Partnership With Growth Market India Goes Deeper With Second Local R&D Center (MedTech Insight)
• Backed By $29M, Sunrise Automates Workflow Using AI To Scale Sleep Care Across US (MedTech Insight)

• From hamburger stand to $1B beverage brand: A look inside Milo’s sweet tea empire (Food Dive)
• New FDA programs designed to enhance transparency of outbreak investigations (Food Safety News)

• US health agency has sent drug pricing pilot to the White House (Reuters)
• Anthony Letai of Dana-Farber is front-runner to lead National Cancer Institute (STAT)
• House Democrat introduces articles of impeachment against RFK Jr. (The Hill)
• Democrats bet the House on health care (The Hill)
• California’s Novel Approach to Controlled Substance Inventory and Loss Reporting (FDA Law Blog)